Technicals show structural failure, not a healthy reset — MACD bearish crossover active with price below VWMA and testing 200 SMA from below

• MACD bearish crossover on August 27 with histogram expanding negative to -0.94
• Price closed below 10 EMA ($112.07), Bollinger middle band, AND rising 200 SMA ($105.56) in a single session
• Price below VWMA at $112.79 — buyers from August rally are underwater
• ATR expanded to 2.69 on a $109 stock (2.5% daily volatility)
• ABT fell from ~$134 in September 2025 to ~$84 in May 2026 (~37% drawdown)
• Currently at $109, still down ~19% from a year ago
• Testing 200 SMA from below after barely recapturing it — 'fragility, not strength'

↩ rebuts: “The bull's claim that RSI collapse to 50 signals 'sellers exhausting themselves'”

The catalyst stack is real but front-loaded in PR value and back-loaded in earnings impact — the market has had a full week with the news and the stock dropped 2.2%

• ABT closed at $111.59 and gapped down to $108.93 on September 1 (-2.2% on a day the broader market gained)
• Libre Duo 10 Day generates lower revenue per sensor than 14-day standard Libre
• Dexcom already dominates integrated insulin pump ecosystem (Tandem, Insulet, Omnipod)
• Abbott 'planning integration over the coming years' — multi-year revenue path, not near-term catalyst
• CE mark for LAA closure is European approval only; U.S. FDA approval is separate and longer
• Boston Scientific's WATCHMAN franchise is mature and embedded with U.S. electrophysiologists
• Medicare CGM coverage expansion is a binary, uncertain outcome — if CMS denies or delays, stock has nothing to lean on
• Similac whole-milk liquid formula is a single SKU in a mature, low-growth nutrition category with secular pricing pressure

↩ rebuts: “The bull's 'most catalyst-rich week in recent history' framing”

Q1 2026 shows structurally impaired earnings profile from the $20B acquisition — not 'non-recurring integration noise'

• Revenue: $11.16B (+7.8% YoY)
• Operating income: $1.35B vs. $2.05B in Q1 2025 — a 37% collapse
• SG&A surged from $3.06B to $3.74B (+22%) in a single quarter
• Net income down 19% YoY
• EPS: $0.61 vs. higher comparable quarters
• Goodwill + intangibles: $23.6B
• Amortization burden: $1.7–2.0B annually (a permanent earnings drag, not non-recurring)
• If acquired business generates $1B in annual EBITDA, Abbott paid 20x EBITDA for the deal

↩ rebuts: “The bull's claim that Q1 2026 numbers are 'non-recurring integration noise'”

Balance sheet now resembles a late-stage LBO with 5x increase in net debt and negative tangible book value

• Total debt: $34.0B (up 146% from $13.9B)
• Net debt: $27.2B (up from $4.4B — a 5x increase)
• Net Debt/EBITDA: 2.3x (vs. historical 0.5–1.0x average — 2–4x deterioration)
• Tangible book value: -$1.0B
• Debt/Equity: 63.2% (vs. historical ~26%)

↩ rebuts: “The bull's claim that 2.3x Net Debt/EBITDA is 'comfortable'”

ABT is trading at the bull's own fair value with no margin of safety and downside skew if earnings disappoint

• Forward EPS consensus: $6.06
• Forward P/E of 18x × $6.06 EPS = $109 (the bull's own fair value estimate)
• If EPS normalizes to $5.50 instead of $6.06, fair value drops to ~$99 (10% downside from current)
• PEG: 2.25 (above 2 means stock is priced for growth it hasn't delivered)
• TTM P/E: 35x
• At 15x P/E instead of 18x, implied price = $91

↩ rebuts: “The bull's celebration of forward P/E of 17.96x as 'reasonable'”

Higher-for-longer rates compress dividend multiples, not expand them — the macro defense doesn't hold

• 89% odds of no Fed cuts in 2026
• When 10-year yield is structurally higher, present value of every future dividend dollar is lower
• ABT's 2.28% yield becomes LESS attractive relative to risk-free alternatives
• Beta of 0.58 means ABT underperforms in rallies
• ABT has underperformed the broader healthcare sector for a full year

↩ rebuts: “The bull's claim that 'higher-for-longer rates actually HELP dividend payers'”

The 'underperformance is the trade' argument is a value trap — being 'loaded with catalysts' in May 2025 preceded a 37% decline to $84

• ABT was 'beaten down but loaded' in May 2025 and then fell another 37% to $84
• Institutional accumulation before retail is NOT a reliable timing signal (cited Theranos, WeWork, Valeant as examples of institutions wrong)
• Integration of a $20B deal takes 24–48 months minimum
• Zero Reddit posts is a signal nobody cares — slow bleed potential
• ABT at 15x P/E instead of 18x = $91 (another leg down)

↩ rebuts: “The bull's 'when fundamentals are improving and price hasn't caught up, that's a setup' claim”

Dividend floor has a crack — if FCF drops 15–20% due to integration costs, coverage drops from 57% to ~70%, forcing a 'hold steady' posture and multiple compression

• Dividend payout: $4.12B annually
• TTM FCF: $7.21B
• Coverage ratio: ~57% (FCF/dividend)
• Annualized dividend per share: ~$2.44
• Payout ratio: ~40%
• If FCF drops 15–20%, coverage drops to ~70%
• Dividend growers with frozen payouts get multiple compression AND yield compression
• ABT at a 15x P/E instead of 18x = $91

↩ rebuts: “The bull's framing of the dividend as a 'floor'”